SCHEMBL5768447

SCHEMBL5768447

O=C1c2c(c(O)c3nccnc3c2O)C(=O)N1Cc1ccc(F)c(Br)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.41
KDM4E B2RXH2 3/20 0.39
FAAH O00519 1/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CA7 P43166 1/20 0.36
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
MAOB P27338 3/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1B1 Q16678 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5767322 0.88 ALDH1A1 (0.37) CA12CA1CA2CA9HDAC4
SCHEMBL6102479 0.85 PARP1 (0.41) PARP1KDM4ECA12CA1CA2
SCHEMBL6102631 0.81 CHRM5 (0.41) CA12CA1CA2CA9CA7
SCHEMBL4150996 0.81 CYP1A2 (0.51) CA12CA1CA2CA9CYP1A2
SCHEMBL5769930 0.80 CYP1A2 (0.33) CA12CA1CA2CA9MAOB
SCHEMBL5797066 0.80 GRM5 (0.39) MAOBCHRM5
SCHEMBL6101670 0.80 KDM4E (0.42) KDM4ECA12CA1CA2CA9
SCHEMBL5796643 0.80 CYP1A2 (0.37) CA12CA1CA2CA9CYP1A2
SCHEMBL5766292 0.80 CA12 (0.41) KDM4ECA12CA1CA2CA9
SCHEMBL6098180 0.80 UBE2N (0.45) CA12CA1CA2CA9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211724-A1 Hiv integrase inhibitors VERSCHUEREN GASTON W 2006-09-21 US claimed
EP-1625130-A2 HIV INTEGRASE INHIBITORS Tibotec Pharmaceuticals Ltd. (IE) 2006-02-15 EP claimed
WO-2004096807-A2 HIV INTEGRASE INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2004-11-11 WO claimed
US-20060211724-A1 Hiv integrase inhibitors VERSCHUEREN GASTON W 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211724-A1 Hiv integrase inhibitors SULT1A1, SULT2A1, SULT1E1 PARP1 1882/4885KDM4E 4133/4885FAAH 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.